|
CD8 Deficiency, Familial
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
CD8 Deficiency, Familial
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Bronchiectasis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Recurrent viral infection
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Recurrent bacterial infection
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Recurrent respiratory infections
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Absence of CD8-positive T cells
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
<b>Materials and methods:</b> In the present study, we reanalyzed data from four public datasets (the Cancer Genome Atlas for investigation; and CIT, GSE5287, and GSE31684 for validation) to examine the prognostic significance of CD3D, CD4, CD8A, CD3D/CD4 and CD3D/CD8A in MIBC.
|
31114346 |
2019 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
<b>Materials and methods:</b> In the present study, we reanalyzed data from four public datasets (the Cancer Genome Atlas for investigation; and CIT, GSE5287, and GSE31684 for validation) to examine the prognostic significance of CD3D, CD4, CD8A, CD3D/CD4 and CD3D/CD8A in MIBC.
|
31114346 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Methods:</b> Seven syngeneic mouse tumor models (B16F10, P815, CT26, MC38, Renca, 4T1, Sa1N) were quantified for CD4<sup>+</sup> and CD8a<sup>+</sup> TILs using flow cytometry and immunohistochemistry (IHC), as well as for tumor growth response to Sym021, a humanized PD-1 antibody cross-reactive with mouse PD-1<b>.</b> Radiotracers were generated from F(ab)'2 fragments of rat-anti-mouse CD4 and CD8a antibodies conjugated to the <i>p</i>-SCN-Bn-Desferrioxamine (SCN-Bn-DFO) chelator and radiolabeled with Zirconium-89 (<sup>89</sup>Zr-DFO-CD4/<sup>89</sup>Zr-DFO-CD8a).
|
31754392 |
2019 |
|
Chronic sinusitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CD8A gene polymorphisms predict severity factors in chronic rhinosinusitis.
|
23640800 |
2013 |
|
Sjogren's Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
CD8a knockout abrogated the development of SS in these mice.
|
30035379 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD8A expression was significantly upregulated in POLE category tumors compared with that in nonhypermutators.
|
31240875 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A DOX-loaded polysaccharide-lecithin reverse micelles triglyceride-based oral delivery nanocarrier (D-PL/TG NPs) conjugated with (i) RGD peptide for targeting to β1 integrin of M cells and (ii) Lyp-1 peptide for targeting to the p32 receptor of MDA-MB-231 cells is used to investigate the multistage continuous targeting capabilities of these peptide-conjugated nanocarriers (GLD-PL/TG NPs) for tumor therapy.
|
27634372 |
2017 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Affect of the p32 inhibitor on glioma cell proliferation was assessed by Alamar Blue assay, and affect on metabolism was examined by measuring lactate secretion.
|
29047383 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After primary tumour removal, a course of three subcutaneous vaccinations with LLC lysate supplemented with BGs led to a significant increase in overall survival (80% after 84 days of follow‑up vs. 40% in untreated control mice), a significant increase in circulating CD8a+ T cells (16.57 vs. 12.6% in untreated control mice) and a significant decrease in metastasis foci area and incidence.
|
27878261 |
2017 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
After primary tumour removal, a course of three subcutaneous vaccinations with LLC lysate supplemented with BGs led to a significant increase in overall survival (80% after 84 days of follow‑up vs. 40% in untreated control mice), a significant increase in circulating CD8a+ T cells (16.57 vs. 12.6% in untreated control mice) and a significant decrease in metastasis foci area and incidence.
|
27878261 |
2017 |
|
Infection caused by Coxiella
|
0.010 |
Biomarker
|
disease |
BEFREE |
Also during Coxiella infection binding of AnkG to p32 and Importin-α1 is crucial for nuclear localization of AnkG.
|
27328359 |
2017 |
|
Rheumatoid Arthritis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Although the frequencies of B3, Km, and CD8A genotypes were not different between RA and normal control populations, more individuals were homozygous for both C kappa and B3 in the RA group (relative risk 2.2, P less than 0.01), especially in the DR4-negative RA subgroup (relative risk 3.9, P less than 0.001).
|
1731812 |
1992 |
|
Rheumatoid Arthritis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Among unrelated individuals with rheumatoid arthritis (RA) and controls, there is no evidence of allelic association between CD8A and polymorphic markers of the immunoglobulin kappa region [a V kappa (IGKV) BglII polymorphism about 24 kb centromeric to C kappa, Km allotype, and a SacI polymorphism 3.5 kb telomeric to the C kappa segment].
|
1349568 |
1992 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Analysis of tumour CD8A expression in the independent validation cohort revealed similar variation in prognostic value across risk strata (P<sub>INTERACTION</sub> = 0.048).
|
31388185 |
2019 |
|
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Application of polymersomes engineered to target p32 protein for detection of small breast tumors in mice.
|
29721153 |
2018 |
|
Avascular retina
|
0.010 |
Biomarker
|
disease |
BEFREE |
Areas of the avascular retina and intravitreal neovascularization were determined in flat mounted retinas stained with isolectin B4 on P32.
|
29259390 |
2017 |
|
Endothelial dysfunction
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Arginase activity, p32 protein expression, spermine amount, and [Ca<sup>2+</sup>]m were increased in the aortas from apolipoprotein E (ApoE<sup>-/-</sup>) mice fed a high-cholesterol diet, and intravenous administration of small interfering RNA against p32 restored Ca<sup>2+</sup>/Ca<sup>2+</sup>/calmodulin-dependent kinase II -dependent eNOS Ser1177 phosphorylation and improved endothelial dysfunction.
|
30371203 |
2018 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
As p32 is overexpressed and surface displayed in breast cancers, we studied the efficacy of the nanosystem in this cancer.
|
23959073 |
2013 |